Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)

COVID-19 Clinical Trial

Official title:

A Randomised Controlled Trial to Assess the Immunogenicity, Safety & Reactogenicity of Standard Dose Versus Fractional Doses of COVID-19 Vaccines (Pfizer-BioNTech, AstraZeneca or Moderna) Given as a Booster Dose After Priming With Coronavac or AstraZeneca in Healthy Adults in Indonesia

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05387317
• Other study ID #: RCH HREC Ref 81803
• Status: Withdrawn
• Phase: Phase 3
• Start date: April 2024
• Est. completion date: October 2025

Study information

• Verified date: March 2024
• Source: Murdoch Childrens Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomised controlled clinical trial to determine the reactogenicity and immunogenicity of booster doses of SARS-CoV-2 vaccines (Pfizer-BioNTech, AstraZeneca or Moderna) in adults who have previously received either AstraZeneca or Coronavac as their primary doses.

Both fractional and standard doses of Pfizer-BioNTech, AstraZeneca and Moderna will be tested.

Description:

There will be a total of 800 participants in the study, to be randomised and administered booster doses in this study.

The study will be conducted at 3 clinics in Bandung. Participants will have previously received primary doses of Coronavac or Astranzeneca, with the second dose administered at least 6 months previously.

Participants will be followed for 12 months following the booster vaccine adminstration, with blood samples drawn at baseline, 28 days, 6 months and 12 months following booster vaccine administration.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Clinically healthy adults aged 18 years and above who had completed the primary series of COVID-19 vaccine with CoronaVac or AstraZeneca more than 6 months prior to enrolment to the study.

2. Signed written informed consent form and willing to comply with the instructions of the investigator and the schedule of the trial.

Exclusion Criteria:

1. Those who have already received a third dose of SARS-CoV-2 vaccine

2. Concomitantly enrolled or scheduled to be enrolled in another trial.

3. Those with fever (temperature ? 37.5?, measured with infrared thermometer/thermal gun), upper respiratory tract infection symptoms such as sneezing, nasal congestion, runny nose, cough, sore throat, loss of taste, chills and shortness of breath within 72 hours before enrolment.

4. Blood pressure ? 180/110 mmHg.

5. History of confirmed COVID-19 within one month prior to study enrolment.

6. History of allergy to vaccines or vaccine ingredients, and severe adverse reactions to vaccines, such as urticaria, dyspnoea, and angioneurotic oedema.

7. Those with uncontrolled autoimmune disease such as systemic lupus erythematosis.

8. History of uncontrolled coagulopathy or blood disorders, immune deficiency.

9. History of having received blood derived product/transfusion within 3 months prior to enrolment.

10. Those who received immunosuppressant therapy such as high-dose corticosteroid or cancer chemotherapy

11. Those with uncontrolled chronic disease, such as severe heart disease, asthma exacerbation

12. Those who have history of uncontrolled epilepsy (within the last 2 years) or other progressive neurological disorders, such as Guillain-Barre Syndrome

13. Those who have receive any vaccination within 2 weeks before study vaccine administration for this protocol, or intended to receive any vaccination within 2 weeks after study vaccine administration.

14. Pregnant woman

15. Those aged =60 years old with difficulty in climbing 10 steps of stairs, frequently experiencing fatigue, difficulty in walking 100-200 m, or having at least 5 comorbidities (hypertension, diabetes, cancer, chronic lung disease, heart attack, congestive heart failure, chest pain, asthma, joint pain, stroke, and kidney disease).

16. Those who are study staff working on the study or the immediate family of study investigators

Related Conditions & MeSH terms

• COVID-19

Intervention

Biological:
• Pfizer-BioNTech Standard dose
Standard Dose - (30ug in 0.3ml) The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA).
• AstraZeneca Standard dose
Standard Dose (5xE10vp in 0.5ml) ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein
• Pfizer-BioNTech Fractional dose
Fractional Dose - (15ug in 0.15ml) The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA).
• AstraZeneca Fractional dose
Fractional Dose (2.5E10vp in 0.25ml) ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein
• Moderna Standard dose
Standard dose (50ug in 0.25ml)
• Moderna Fractional dose
Fractional dose (20ug in 0.1ml)

Locations

Country	Name	City	State
Indonesia	Puskesmas Ciumbuleuit	Bandung	West Java
Indonesia	Puskesmas Dago	Bandung	West Java
Indonesia	Puskesmas Garuda	Bandung	West Java

Sponsors (6)

Lead Sponsor	Collaborator
Murdoch Childrens Research Institute	Coalition for Epidemic Preparedness Innovations, Health Development Policy Agency, Ministry of Health Republic of Indonesia, Indonesia University, The Peter Doherty Institute for Infection and Immunity, Universitas Padjadjaran

Country where clinical trial is conducted

Indonesia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SARS-CoV-2 specific Immunoglobulin (Ig)G antibodies at 28-days post booster vaccination	Serum samples collected at 28-days post booster vaccination from all groups will be evaluated for SARS-CoV-2 specific IgG antibodies using IgG CMIA. The primary endpoint is the seroresponse rate at the Day-28 visit. The Seroresponse rate at the individual level is defined as either a =4-fold rise in binding antibodies at the Day-28 visit compared to baseline (pre-vaccination) with a titre of <200 BAU/ml, a =2-fold rise among participants with a baseline (pre-vaccination) titre of >=200 BAU/ml, or =4 times the lower limit of detection if baseline levels are lower than the limit of detection.	Assessed at 28 days
Primary	Incidence of solicited systemic and local reactions (reactogenicity)	Questionnaire to document solicited reactions is developed specifically for this study. Data will be reported as the proportion of participants who report grade 3 or 4 reactions by each intervention arm. Solicited reactions such as pain, tenderness, erythema/redness, induration, swelling, fever, nausea, vomiting, headache, fatigue/malaise, myalgia, arthralgia, diarrhea, enlarged lymph nodes will be collected from the participants 7 days post-vaccination.	Assessed for 7 days post-vaccination
Secondary	SARS-CoV-2 specific IgG antibodies at baseline (pre booster), 6- and 12-months post booster vaccination.	Serum samples collected at baseline (pre booster), 28 days, and 6- and 12-months post booster vaccination from all groups will be evaluated for SARS-CoV-2 specific IgG antibodies using IgG CMIA. Data will be reported as binding antibody units (BAU)/mL and presented as geometric mean concentration (GMC) and 95% confidence intervals (CI)	Assessed at time-points: baseline, 28 days, 6 months, and 12 months).
Secondary	SARS-CoV-2 specific neutralising antibodies at baseline (pre booster), 28 days-, 6- and 12-months post booster vaccination measured by surrogate virus neutralization test (sVNT)	Serum samples collected at baseline (pre booster), 28 days-, 6- and 12-months post booster vaccination from all groups will be evaluated for SARS-CoV-2 specific neutralising antibodies using the GenScript® cPass surrogate virus neutralization test (sVNT) for both wild-type and Omicron variant. Neutralising antibody response will be reported as percentage (%) inhibition of receptor binding domain-angiotensin-converting enzyme 2 (RBD-ACE2) binding relative to a positive control.	Assessed at 4 time-points (baseline, 28 days, 6 months, and 12 months).
Secondary	SARS-CoV-2 specific neutralising antibodies at baseline (pre booster), 28 days-, 6- and 12-months post booster vaccination measured by SARS-CoV-2 microneutralisation assay	A subset of samples from all four timepoints will be assessed using a SARS-CoV-2 microneutralisation assay to both the wild type (vaccine) strain and for two SARS-CoV-2 Variants of concern. Neutralizing antibody will be reported as endpoint titre.	Assessed at 4 time-points (baseline, 28 days, 6 months, and 12 months).
Secondary	Interferon gamma (IFN?) concentrations in International Units (IU)/mL	Applicable to the subset participants with additional blood collection. Interferon gamma (IFN?) concentrations as a measurement of cellular immunity will be assessed on a subset of the participants from each group. QuantiFERON Human IFN-? SARS-CoV-2 (Qiagen) will be used to stimulate IFN-? production in peripheral blood mononuclear cells (PBMCs) and then IFN-? production will be measured using ELISA (enzyme-linked immunosorbent assay). Data will be presented as geometric mean concentration (GMC) and 95% confidence intervals (CI).	Assessed at 4 time-points (baseline, 28 days, 6 months, and 12 months).
Secondary	Number of IFN? producing cells/million PBMCs	Applicable to the subset participants with additional blood collection. IFN? producing cells as a measurement of cellular immunity will be assessed on a subset of the participants from each group. IFN-? Enzyme-Linked ImmunoSpot (Elispot) assay will be performed on isolated peripheral blood mononuclear cells (PBMCs). Data will be reported as number of IFN? producing cells/million and presented using means and 95% confidence intervals.	Assessed at 4 time-points (baseline, 28 days, 6 months, and 12 months).
Secondary	Frequency of cytokine-expressing T cells	Applicable to the subset participants with additional blood collection. Frequency of cytokine-expressing T cells will be assessed on a subset of participants using Flow cytometry (intracellular staining) on PBMCs samples. Data will be reported as frequency (%) of cytokine-expressing T cells presented as means and 95% CI.	Assessed at 4 time-points (baseline, 28 days, 6 months, and 12 months).
Secondary	Cytokine concentrations following PBMCs stimulation	Applicable to the subset participants with additional blood collection. Cytokine concentrations following PBMCs stimulation will be assessed on a subset (40%) of participants using multiplex cytokine assays.Data will be reported as cytokine concentrations in pg/ml and presented as GMC and 95% CI.IFN-? Elispot, intracellular cytokine assays (flow cytometry) and multiplex cytokine assays will be performed on isolated peripheral blood mononuclear cells (PBMCs)	Assessed at 4 time-points (baseline, 28 days, 6 months, and 12 months).
Secondary	Incidence of unsolicited adverse events (AE)	All unsolicited AE will be collected for 28 days post booster vaccination. Data will be presented as proportion of participants who report unsolicited AE.	28 days post booster vaccination for all AE
Secondary	Incidence of medically attended adverse events	Participants with medically attended AE will be collected for 3 months post booster vaccination. Data will be presented as proportion of participants who report unsolicited AE	3 months post booster vaccination for medically attended AE
Secondary	Incidence of serious adverse events (SAE)	SAE will be collected throughout the follow up period of 12 months. Data will be presented as a proportion of participants who report SAE.	12 months post booster vaccination for SAE
Secondary	Incidence of confirmed COVID-19 infection	Confirmed (Polymerase Chain Reaction [PCR] or rapid antigen test) COVID-19 infections will be documented throughout the follow-up period, by clinical severity	Throughout the follow up period of 12 months.